A monthly period of symptoms associated with benign prostatic hyperplasia

Urology

Volumn 55, Issue 3, 2000, Pages 436-

  Axelrod, David E ^a  

^a RUTGERS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; PROSTATE SPECIFIC ANTIGEN; STEROID 5ALPHA REDUCTASE INHIBITOR;

ADULT; ARTICLE; BIOLOGICAL RHYTHM; CASE REPORT; FOURIER ANALYSIS; HUMAN; MALE; NOCTURIA; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; ULTRASOUND; URODYNAMICS;

EID: 0342980378     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(99)00483-5     Document Type: Article

References (11)

1. McConnel J.D. Epidemiology, etiology, pathophysiology, and diagnosis of benign prostatic hyperplasia. Walsh P.C., Retik A.B., Vaughan E.D., et al. Campbell's Urology. 7th ed. 1998;1429-1452 WB Saunders, Philadelphia.
2. Lepor H. Natural history, evaluation, and nonsurgical management of benign prostatic hyperplasia. Walsh P.C., Retik A.B., Vaughan E.D., et al. Campbell's Urology. 7th ed. 1998;1453-1477 WB Saunders, Philadelphia.
3. Ziada A., Rosenblum M., Crawford E.D. Benign prostatic hyperplasia an overview . Urology. 53:1999;1-6.
4. Partin A.W., Coffey D.S. The molecular biology, endocrinology, and physiology of the prostate and seminal vesicles. Walsh P.C., Retik A.B., Vaughan E.D., et al. Campbell's Urology. 7th ed. 1998;1381-1428 WB Saunders, Philadelphia.
5. Narayan P. Neoplasms of the prostate gland. Tanagho E.A., McAninch J.W. Smith's General Urology. 14th ed. 1995;392-433 Appleton & Lange, Norwalk, Connecticut.
6. Batschelet E: Introduction to Mathematics for Life Sciences, 2nd ed. New York, Springer-Verlag, 1976, pp 446-452.
7. Stern K., McClintock M.K. Regulation of ovulation by human pheromones. Nature. 392:1998;177-179.
8. Winfree AT: The Geometry of Biological Time. New York, Springer-Verlag, 1980.
9. Golomb J., Lindner A., Siegel Y., et al. Variability and circadian changes in home uroflowmetry in patients with benign prostatic hyperplasia compared to normal controls. J Urol. 147:1992;1044-1047.
10. Fentiman I.S., Gregory W.M. The hormonal milieu and prognosis in operable breast cancer. Fentiman I.S., Taylor-Papadimitriou J. Breast Cancer. 1993;149-162 Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York.
11. Hrushesky W.J.M., Bjarnason G.A. The application of circadian chronobiology to cancer therapy. DeVita V.T. Jr, Hellman S., Rosenberg S.A. Cancer Principles & Practice of Oncology . 1993;2666-2686 JB Lippincott, Philadelphia.